TY - JOUR
T1 - Levamisole and interferon in children with chronic hepatitis B
AU - Ruiz‐Moreno, Mercedes
AU - García, Rosa
AU - Rua, Maria Jose
AU - Serrano, Beatriz
AU - Moraleda, Gloria
AU - Feijoo, Esperanza
AU - Bartolomé, Javier
AU - Ortiz, Fernando
AU - Castill, Inmaculada
AU - Carreñ, Vicente
PY - 1993/8
Y1 - 1993/8
N2 - To evaluate the possible usefulness of simultaneous administration of levamisole and interferon, we randomly allocated 38 children with chronic hepatitis B to receive either 10 MU/m2 interferon‐α‐2a, three times a week for 6 mo (group 1, n = 20) or 90 mg/m2 of levamisole for 45 days, together with 10 MU/m2 of interferon‐α‐2a, three times a week for 6 mo (group 2, n = 18). At the end of the follow‐up period (15 mo), no significant differences were observed between the groups with respect to loss of hepatitis B virus DNA and HBeAg from serum and normalization of serum ALT levels. During therapy, a significant increase in the serum levels of ALT and soluble interleukin‐2 receptor was observed in both groups but was higher in patients from group 2. The combination of levamisole with interferon was associated with severe side effects. In summary, the combination of levamisole with interferon in children with chronic hepatitis B does not improve the results obtained with interferon alone. (HEPATOLOGY 1993;18:264–269).
AB - To evaluate the possible usefulness of simultaneous administration of levamisole and interferon, we randomly allocated 38 children with chronic hepatitis B to receive either 10 MU/m2 interferon‐α‐2a, three times a week for 6 mo (group 1, n = 20) or 90 mg/m2 of levamisole for 45 days, together with 10 MU/m2 of interferon‐α‐2a, three times a week for 6 mo (group 2, n = 18). At the end of the follow‐up period (15 mo), no significant differences were observed between the groups with respect to loss of hepatitis B virus DNA and HBeAg from serum and normalization of serum ALT levels. During therapy, a significant increase in the serum levels of ALT and soluble interleukin‐2 receptor was observed in both groups but was higher in patients from group 2. The combination of levamisole with interferon was associated with severe side effects. In summary, the combination of levamisole with interferon in children with chronic hepatitis B does not improve the results obtained with interferon alone. (HEPATOLOGY 1993;18:264–269).
UR - https://www.scopus.com/pages/publications/0027200859
U2 - 10.1002/hep.1840180207
DO - 10.1002/hep.1840180207
M3 - Article
C2 - 7687978
AN - SCOPUS:0027200859
SN - 0270-9139
VL - 18
SP - 264
EP - 269
JO - Hepatology
JF - Hepatology
IS - 2
ER -
